Dr. John Heymach is an Assistant Professor of Thoracic Head/Neck Medical Oncology as well as Assistant Professor of Cancer Biology at the University of Texas M.D. Anderson Cancer Center in Houston, TX. Dr. Heymach’s professional research interests include lung cancer, mesothelioma, angiogenesis inhibitors, and biomarker development for targeted agents. He is considered among the most progressive new physicians in the treatment of malignant mesothelioma and other thoracic disease.
Dr. Heymach attended Harvard University College of Medicine, earning his M.D. and Ph.D. and was immediately recruited to begin work at the Dana Farber Cancer Institute in Boston, Massachusetts. While at Dana Farber, Heymach also worked closely with the Brigham and Women’s Hospital in Boston, alongside many of the world’s leading thoracic oncologists including the renowned Dr. David Sugarbaker, who is considered the forefront expert in the treatment of malignant mesothelioma.
Recognizing his talents, Dr. Heymach was recruited from Dana Farber to join the faculty of the M.D. Anderson Cancer Center at the University of Texas. Dr. Heymach has been recognized on a number of occasions by both his peers and professional organizations, earning the ASCO Career Development Award as well as the Damon Runyan Clinical Investigator Award. He is an associate editor for the Journal of Experimental Therapeutics and Oncology as well as an editorial board member of Signaling and Clinical Lung Cancer.
- University of Texas M.D. Anderson Cancer Center. Physician Profile
Last modified: December 24, 2010.